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Abstract
Mutations in PSEN1 and PSEN2 genes account for the majority of cases of early-onset familial
Alzheimer disease. Since the first prediction of a genetic link between PSEN1 and PSEN2 with
Alzheimer's disease, many research groups from both academia and pharmaceutical industry have
sought to unravel how pathogenic mutations in PSEN cause presenile dementia. PSEN genes encode
polytopic membrane proteins termed presenilins (PS1 and PS2), which function as the catalytic
subunit of γ-secretase, an intramembrane protease that has a wide spectrum of type I membrane
protein substrates. Sequential cleavage of amyloid precursor protein by BACE and γ-secretase
releases highly fibrillogenic β-amyloid peptides, which accumulate in the brains of aged individuals
and patients with Alzheimer's disease. Familial Alzheimer's disease-associated presenilin variants
are thought to exert their pathogenic function by selectively elevating the levels of highly
amyloidogenic Aβ42 peptides. In addition to Alzheimer's disease, several recent studies have linked
PSEN1 to familiar frontotemporal dementia. Here, we review the biology of PS1, its role in γ-
secretase activity, and discuss recent developments in the cell biology of PS1 with respect to
Alzheimer's disease pathogenesis.
Background
In 1995 independent groups identified genetic linkage
and mutations within PSEN1  (chromosome 14) and
PSEN2  (chromosome 1) genes in several early onset
familial Alzheimer's disease (FAD) kindreds [1-3]. Since
then a number of research groups have focused on FAD-
linked mutations and the biology of proteins encoded by
these homologous genes. So far 140 and 10 mutations
that co-segregate with FAD (in most cases before 60 years
of age) have been identified in PSEN1 and PSEN2, respec-
tively. PSEN1  and  PSEN2  encode 467 and 448 amino
acid-long polytopic transmembrane proteins, termed
presenilin 1 (PS1) and presenilin 2 (PS2), respectively.
The sequence identity between these two highly con-
served proteins is greater than 65%. PS1 is expressed ear-
lier than PS2 during mouse embryonic development
indicating differential regulation of these proteins during
development [4]. Although PS1 is relatively expressed at
higher levels than PS2, both proteins are ubiquitously
expressed in the brain and peripheral tissues in adult
human and rodent.
Mutations in PSEN1 and PSEN2 are autosomal dominant,
highly penetrant, and cause Alzheimer's disease (AD)
symptoms before age 65, in some cases with onset of
symptoms less than 30 years of age. Even though FAD-
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linked mutations in amyloid precursor protein (APP) and
PSEN genes account for less than 5% of total AD cases, the
phenocopies of these FAD mutations are reminiscent of
late onset sporadic AD. As discussed below, PS1 and PS2
are subunits of a protein complex, termed γ-secretase,
which cleaves several type I membrane proteins including
APP within their transmembrane domain. In the case of
APP, γ-secretase cleavage predominantly generates 39–43
amino acid-long peptides, termed β-amyloid peptides
(Aβ), which accumulate in the brains of aged individuals
and patients with AD. Although the mode of action (gain
of function or loss of function) is still debated, FAD-
linked mutations in PS selectively elevate the levels of
highly amyloidogenic Aβ42 peptides by likely shifting the
cleavage site in APP [5,6]. Nevertheless, FAD mutations
may exhibit partial loss of function in some other physio-
logical activities [7]. Because of its central role in the
pathogenesis of AD, PS became the focus of much scrutiny
and has been considered as a potential therapeutic target
for the treatment of AD. More recently, novel PSEN1
mutations, as well as PSEN1-spliced variants, have been
identified in several familiar frontotemporal dementia
(FTD) kindreds, suggesting that PS1 may also play a role
in FTD pathogenesis [8-12]. But the underlying mecha-
nisms are still elusive. In addition, several studies have
identified physiological functions of PS1 beyond AD and
FTD including apoptosis, calcium homeostasis, neurite
outgrowth, and synaptic plasticity [reviewed in [13]]. In
this chapter, we mainly focus on recent advances in the
cell biology of PS, and discuss the function of PS as it
relates to AD.
PS topology
Determination of PS protein topology is of particular
interest because it may facilitate a better understanding of
the structural and functional relationship of γ-secretase
activity. The transmembrane (TM) topology of PS1 is still
being debated, though several topology models have been
proposed based on different experimental approaches.
Most of these studies use antibodies, engineered N-glyco-
sylation acceptor sites, protease digestion, and gene
fusions with reporters, to map the cytosolic or lumen
regions of the protein. The amino acid sequence of PS
contains ten hydrophobic regions (HR) that can poten-
tially function as TM domains, leading to the proposal of
several models for PS with 6 to 9 TM segments. Neverthe-
less, an eight TM topology model with N- and C-termini,
and a hydrophilic loop domain between TM 6 and 7 fac-
ing the cytosol, has been widely accepted [14] (Fig. 1).
While there is uniform agreement between various mod-
els in cytosolic location of the N-terminus and the TM
assignments of the first six HR, the models differ with
respect to HR seven through ten as membrane spanning
domains; also, the location of PS1 C-terminus has long
been debated as well. A recent study using glycosylation
acceptor sequences also confirmed the luminal orienta-
tion of the first hydrophilic loop and cytosolic orientation
of N-terminus and a large hydrophilic loop (between TM
6 and 7), which are in agreement with the eight TM model
[15]. However, in contrast to the eight TM model, the C-
terminus was found oriented to the lumen suggesting that
an HR near the C-terminus functions as the ninth TM seg-
ment.
Endoproteolysis of PS
PS1 is synthesized as a 42- to 43-kD polypeptide that
undergoes highly regulated endoproteolytic processing
within the large cytoplasmic loop domain connecting
putative TM segments 6 and 7 to generate stable 27- to 28-
kD N-terminal (NTF) and 16- to 17-kD C-terminal (CTF)
fragments [16] by an uncharacterized proteolytic activity.
Endoproteolytic processing of PS is a highly conserved
and, perhaps, a critical event that regulates the stability of
PS1 and possibly the biological activity of PS. While full
length PS1 is relatively short-lived with a half-life of 1–2
h, endoproteolytically processed derivatives (NTF and
CTF) have a half-life of 24 h [17,18]. Moreover, the endo-
proteolytic event has been identified as the activation step
in the process of PS1 maturation as it assembles with
other γ-secretase subunits nicastrin, APH-1, and PEN-2
(described below) [19]. Exception to this initial activation
event is the maturation of FAD-associated PS1∆E9 variant,
which lacks a region including the endoproteolytic cleav-
age site encoded by exon 9 (Fig. 1). PS1∆E9 holoprotein
is metabolically stable, forms a complex with other γ-
secretase subunits and generates functional γ-secretase
activity.
In transfected cells only a fraction of overexpressed PS1 is
converted to stable NTF and CTF, whereas the vast major-
ity of nascent PS1 holoprotein is highly unstable and is
rapidly degraded. The process of PS1 endoproteolysis is a
tightly regulated and saturable event, with PS1 NTF and
CTF accumulating in 1:1 stoichiometry [16,20]. Trans-
genic overexpression of human PS1 in mice replaces
endogenous mouse PS1 by a highly selective and compen-
satory mechanism, and the extent of replacement is pro-
portional to the level of exogenous PS1, which suggests
that exogenous and endogenous PS compete for limiting
cellular factors [16,20]. In cells co-expressing PS1 and
PS2, the assemblies consist of either of PS1 derivatives or
PS2 derivatives but not mixed assemblies (for example,
PS1NTF•PS2CTF). However, expression of chimeric PS1/
PS2 holoprotein is endoproteolysed and forms hetero-
meric assemblies made of PS1NTF•PS2CTF [21]. Further-
more, exogenous PS1 NTF does not co-assemble with
endogenous PS1 CTF. Nevertheless, co-expression of
exogenous NTF and CTF can reconstitute functional γ-
secretase in PS-deficient cells [22,23]. These findings indi-
cate that association between N- and C-terminal domainsMolecular Neurodegeneration 2006, 1:4 http://www.molecularneurodegeneration.com/content/1/1/4
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of PS1 holoprotein occurs prior to endoproteolysis; and
following assembly, PS-derived NTF/CTF do not exchange
between γ-secretase complexes containing either PS1 or
PS2.
Experimental deletion and replacement mutants and
domain swap experiments have been useful in identifying
amino acid residues that are critical for PS1 endoproteol-
ysis as well as γ-secretase activity. Deletions and substitu-
tions near the putative endoproteolytic cleavage sites
between Thr291 and Ala299 [17] abolished PS1 endopro-
teolysis, but the resulting stable holoprotein still retained
γ-secretase activity [24]. In contrast, aspartate residues at
position D275 (in TM6) and D385 (in TM7) of PS1 are
critical for both PS1 endoproteolysis and γ-secretase func-
tion [25]. Furthermore, residues critical for both PS1
endoproteolysis and γ-secretase activity have been identi-
fied within TM1 of PS1 [26]. These findings have been
inconclusive with reference to the correspondence
between PS endoproteolysis and γ-secretase activities.
With a few exceptions, well-characterized and highly
potent γ-secretase inhibitors do not affect PS1 endoprote-
olysis, providing more definite proof that PS endoproteol-
ysis and γ-secretase activity is pharmacologically distinct
[27]. The enzyme activity responsible for PS1 endoprote-
olysis has not been identified. Based on the available data
one cannot exclude the possibility that PS1 endoproteol-
ysis may be an autocatalytic event, which occurs during
the maturation of unstable nascent PS1 holoprotein into
stable derivatives. Clues from the deletion of domains far
from the endoproteolytic site are consistent with a poten-
tial conformational change associated with the process of
PS1 endoproteolysis and maturation. For example, dele-
tion of TM1 through TM2 (PS1∆M12) resulted in an
endoproteolysis-defective mutant, which unlike PS1 hol-
oprotein is extremely stable [28,29]. Interestingly, a large
hydrophilic loop domain connecting the TM domain 6
and 7 (residues 304–371) of PS1, which includes a cas-
pase cleavage site (D345) and serves as the interaction
domain for several PS-associated proteins, is dispensable
for PS1 endoproteolysis and γ-secretase activity [30].
PS-dependent γ-secretase is involved in intramembranous 
proteolysis of type I membrane proteins
In the past few years there has been accumulating interest
in understanding regulated cleavage of type I membrane
Schematic representation of PS1 structure Figure 1
Schematic representation of PS1 structure. In this model, PS1 is depicted to traverse the membrane eight times. Each 
circle represents an amino acid, and shaded circles represent individual residues mutated in FAD cases. In addition to point 
mutations, two deletion mutations I83/M84 and S290–S319 have been identified. Arrow marks the major site of endopro-
teolytic cleavage, which occurs when nascent PS1 molecule assembles with nicastrin, APH-1 and PEN-2.
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proteins within their transmembrane domains. Aβ40 and
Aβ42 peptides are released from APP by intramembra-
nous cleavage at two major sites within the TM. In keeping
with the nomenclature of previously described α- and β-
secretase cleavage of APP within the extracellular domain,
the intramembranous cleavage of APP was termed the "γ-
secretase" cleavage. The realization that cleavage at one of
the sites that corresponds to +42 residue of Aβ is enhanced
2-fold in FAD cases [6] led to increased scrutiny of this
cleavage process. De Strooper and colleagues [31] first
reported a direct role for PS1 in this process when they
noted loss of Aβ secretion and accumulation of APP C-ter-
minal fragments (CTF) in PS1-/- neurons. Soon after, a
striking similarity between PS-mediated cleavage of APP
and the proteolytic cleavage of transmembrane Notch
receptor began to emerge [32-34]. In both cases, mem-
brane tethered CTF, rather than the full-length proteins,
serves as the substrates for γ-secretase cleavage. Struhl and
Adachi [35] systematically examined the requirements for
PS1/γ-secretase cleavage and concluded that PS1 can
mediate sequence-independent cleavage of a diverse set of
transmembrane proteins with short extracellular
domains. Consistent with APP and Notch processing,
cleavage efficiency of experimental proteins was inversely
proportional to the length of the extracellular domain of
the proteins [35].
As expected from the relaxed sequence specificity of γ-
secretase, a wide range of type I transmembrane substrates
has been described within the last few years, extending a
physiological role for PS1 beyond the nervous system and
AD (Fig. 2). These include homologues of APP (APLP1
and APLP2) [31,36], Notch1 homologues [32-34], Notch
ligands Delta and Jagged [37], the receptor tyrosine kinase
ErbB-4 [38], cell surface adhesion protein CD44 [39], the
mucin-type molecule CD43 [40], low-density lipoprotein
receptor-related protein [41], cell adhesion receptors N-
and E-cadherins [42,43], cadherin-related gamma-proto-
cadherins [44], synaptic adhesion protein nectin-1α [45],
netrin receptor DCC [46], cell surface heparin sulphate
proteoglycan syndecan-3 [47], p75 neurotrophin receptor
[48] and its homolog NRADD [49], the voltage-gated
sodium channel β2-subunit [50], tyrosinase and tyrosi-
nase-related proteins 1 and 2 [7] etc. As with the case of
APP and Notch1, γ-secretase cleavage of these additional
substrates is preceded by cleavage(s) within their extracel-
lular domain. In several cases PS1/γ-secretase cleavage
releases an intracellular domain analogous to Notch intra-
cellular domain that can translocate into the nucleus. It
remains to be determined whether intracellular domains
of all γ-secretase substrates engage in signal transduction
upon gaining entry into the nucleus. For example, γ-secre-
tase cleavage of DCC terminates the cAMP/PKA signaling
cascade and potentially modulates glutamatergic synaptic
transmission in neurons [51].
PS1 stability and functions in γ-secretase require other 
components
As described above, overexpression of PS1 alone neither
substantially increases the levels of mature PS1 derivatives
nor elevates Aβ generation in cultured cell lines and trans-
genic mice. Based on these findings, a model was pro-
posed wherein the abundance of mature PS1 fragments is
regulated by interaction with limiting cellular factor(s)
[20]. Genetic and biochemical approaches have identified
three additional proteins that are crucial for the stability
of PS1 as well as γ-secretase activity. Goutte and colleagues
used genetic screens to identify two genes, named aph-1
and aph-2 (anterior pharynx defective), which act in the
GLP-1/Notch pathway during the early stages of C. elegans
embryogenesis [52,53]. A type I transmembrane protein
termed Nicastrin, which is the mammalian homolog of
aph-2, was identified simultaneously by biochemical
methods as a protein bound to PS1 [54]. An independent
C. elegans genetic screen identified aph-1  and  pen-2  as
enhancers of sel-12/Presenilin function, and showed that
aph-2, aph-1 and pen-2 are required for Notch signaling,
PS1 accumulation, and γ-secretase activity [55]. APH-1 is
a multipass transmembrane protein encoded by two
(human) or three (rodent) genes that can be alternatively
spliced. PEN-2 is a protein with two transmembrane
domains encoded by one gene. It is now clear that PS,
nicastrin, APH-1, and PEN-2 are stoichiometric compo-
nents of high molecular weight γ-secretase complex. Co-
expression of these four transmembrane proteins is suffi-
cient to reconstitute γ-secretase activity in yeast, which
lacks these mammalian orthologs [56]. Furthermore, co-
expression of all four proteins is sufficient to overcome
the limitation in generating excess PS-derived NTF and
CTF in transfected cells [57-59]. Thus, PS1 endoproteoly-
sis, stability and accumulation of PS1 NTF/CTF are regu-
lated by the availability of stoichiometric levels of
nicastrin, APH-1 and PEN-2. Most interestingly, biogen-
esis, maturation, stability, and the steady state levels of γ-
secretase components are co-dependent. Down regulation
or targeted gene disruption of any one of these compo-
nents affects maturation and stability of other subunits,
indicating that their assembly into a high molecular
weight complex is a highly regulated process that occurs
during biosynthesis of these polypeptides. For example,
the heavily glycosylated type I membrane protein nicas-
trin does not mature and exit the ER in cells lacking PS1
expression [60]. PS1 deficiency also leads to altered intra-
cellular trafficking of PEN-2 and APH-1, as well as their
destabilization [61,62]. On the other hand, PS1 fails to
undergo endoproteolysis to generate stable NTF and CTF
in nicastrin-/- cells or when PEN-2 is downregulated by
RNAi [62-64].
The sequence of events in the assembly of the γ-secretase
complex is only beginning to unravel at this time. Availa-Molecular Neurodegeneration 2006, 1:4 http://www.molecularneurodegeneration.com/content/1/1/4
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ble evidence supports the formation of an early interme-
diate sub-complex made of APH-1 and nicastrin [65]. The
proximal C-terminus region PS1 holoprotein then binds
to this subcomplex by interacting with nicastrin TM
domain [66]. During the final step in the assembly, PEN-
2 associates with the complex by interaction with TM 4 of
PS1 2 [67,68], concurrent with PS1 endoproteolysis. The
observation that membrane-permeable γ-secretase inhibi-
tors markedly increase cell surface levels of PS1 and PEN-
2 without affecting that of nicastrin also implies a tighter
association between PS1 and PEN-2 [61]. Despite the
identification of the core components, the precise stoichi-
ometry of the active γ-secretase complex remains obscure.
First, the existence of distinct subsets of γ-secretase com-
Multifaceted functions of PS1 mediated through the interacting proteins Figure 2
Multifaceted functions of PS1 mediated through the interacting proteins. The figure represents the multiple roles of 
PS1 in cellular functions. PS1 associates with nicastrin, APH-1 and PEN-2 to form the γ-secretase, which cleaves a set of type I 
membrane protein substrates including APP and Notch. Transmembrane proteins CD147 and p23/TMP21 have been shown to 
interact with γ-secretase complex and modulate Aβ production. In addition, PS1 interacts with several proteins that are 
involved in important physiological functions such as calcium homeostasis, vesicular transport, cell adhesion, etc. Trafficking of 
certain membrane proteins, including some γ-secretase substrates also seems to be influenced by PS1 deficiency, inhibition of 
γ-secretase activity, or expression of FAD-linked PS1 variants.
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plexes consisting of different PS or APH-1 subunits has
been reported from studies conducted in cell culture and
animal models [69,70]. Second, a recent study demon-
strated the existence of PS dimer at the core of the γ-secre-
tase complex with the substrates being processed between
the PS monomers [71]. In addition, the use of different
biochemical purification methods and detergents has led
to the apparent size discrepancy of active γ-secretase com-
plexes, with estimates ranging from 250 kDa [58] to 2
MDa [72].
PS1 functions as the catalytic center of γ-secretase
The exact functional contribution of each γ-secretase sub-
unit to enzyme activity still remains elusive. Two lines of
investigation strongly support the notion that PS1 may
form the catalytic center of γ-secretase. First, Wolfe and
colleagues identified the presence of two highly conserved
aspartate residues in transmembrane domains 6 (D257 in
PS1 and D263 in PS2) and 7 (D385 in PS1 and D366 in
PS2) that are indispensable for γ-secretase activity, and
suggested that γ-secretase is a transmembrane aspartyl
protease [25]. Second, it was found that highly specific
transition-state analogue inhibitors of γ-secretase specifi-
cally bound to PS1 NTF/CTF heterodimer [73]. As dis-
cussed above, the stoichiometry of γ-secretase subunits
has not been firmly established. A recent study demon-
strated the existence of PS dimer at the core of γ-secretase
complex and proposed a model where the substrates are
processed between the PS monomers [71]. Interestingly,
APP and Notch can interact with PS1 in the presence of
active site γ-secretase inhibitors, revealing the presence of
a docking site within PS1 that is distinct from the catalytic
site [74,75]. In a recent study Yu and colleagues reported
that the extracellular domain of nicastrin interacts with
ectodomain cleaved APP and Notch, and thus functions
as the γ-secretase substrate receptor [76]. A recent study
suggested that a widely expressed cell surface type I trans-
membrane glycoprotein CD147 (also called basigin and
EMMPRIN) may function as a regulatory subunit of the γ-
secretase complex [77]. Downregulation of CD147
expression caused a modest increase in Aβ production.
Interestingly, unlike the integral γ-secretase components,
overexpression or downregulation of CD147 did not
affect the stability of γ-secretase complex [77]. Similarly, a
recent study reported that p23/TMP21, a member of the
p24 family of transmembrane proteins involved in vesicle
trafficking between the ER and Golgi apparatus binds to γ-
secretase complex. Knockdown of p23/TMP21 expression
did not affect the steady-state levels of γ-secretase subu-
nits, but resulted in increased generation of Aβ40 and
Aβ42 peptides without affecting ε-cleavage of APP or
Notch [78]. Despite these recent advances, it is still
intriguing how FAD-associated point mutations that are
widely scattered throughout the protein, many of which
are located far away from the putative catalytic site, selec-
tively alter the cleavage site preference in APP in a manner
that increases Aβ42 production.
Subcellular localization of PS1
PS1 has been localized to multiple organelles including
the endoplasmic reticulum (ER), ER/Golgi intermediate
compartments, Golgi apparatus, endosomes, lysosomes,
phagosomes, plasma membrane, and mitochondria.
Quantitative immunoelectron microscopy estimates of
endogenous PS1 in CHO cells showed that the vast major-
ity (52%) of PS1 is present in pre-Golgi membranes that
include nuclear envelope, ER and vesicular-tubular clus-
ters that are positive for COP1, whereas only about 1% of
total label was localized in the Golgi complex [79]. A sig-
nificant amount of PS1 (25%) was localized in the plasma
membrane and 13% in endocytic compartments. How-
ever, a recent biochemical study estimated that only 6% of
PS1 and γ-secretase activity exists at the cell surface [80].
Consistent with the later estimates, cell fractionation stud-
ies show that the majority of the mature components of
endogenous γ-secretase complex are present in intracellu-
lar organelles [81]. Furthermore, non-ionic detergent
extraction revealed the presence of presenilin and other γ-
secretase subunits in cholesterol- and sphingolipid-rich,
detergent-resistant membrane microdomains of post-
Golgi, TGN and endosome membranes. Association of γ-
secretase components with detergent-resistant mem-
branes is sensitive to cholesterol depletion, fulfilling a
stringent criterion expected of bona fide lipid raft associ-
ated proteins. Using magnetic immunoisolation, active
and mature components of γ-secretase complex were
found to co-reside in lipid raft microdomains with VAMP-
4 (TGN), syntaxin 6 (TGN vesicles) and syntaxin 13 (late
endosomes). Interestingly, the cell-surface raft-associated
protein SNAP-23 does not co-reside with γ-secretase sub-
units, further validating intracellular compartmentaliza-
tion of γ-secretase complex [81].
Differential functions of wild type and FAD-associated PS1 
and PS2
Over 130 mutations (>258 families) in PSEN1  and 9
mutations (15 families) in PSEN2 have been identified as
autosomal dominant, highly penetrant mutations that
cause early-onset AD. In general, mutations in PSEN2 are
associated with a later age of onset compared to PSEN1
(mean familial age of onset 57.1 years and 44.1 years,
respectively) and cause slower disease progression [82].
FAD-linked mutations in PS intriguingly influence γ-secre-
tase cleavage by an elusive mechanism that modulates the
proteolysis of APP to selectively enhance the generation of
highly amyloidogenic Aβ42 peptides [5,6]. However, the
high frequency of FAD-associated mutations in PSEN1
compared to PSEN2 may be an indicator of differential
functions of γ-secretase containing PS1 or PS2. Indeed, in
vivo complementation of PS1 deficiency with PS2 in trans-Molecular Neurodegeneration 2006, 1:4 http://www.molecularneurodegeneration.com/content/1/1/4
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genic mice indicates functionally different roles for PS1
and PS2 [70]. In the absence of PS1, transgenic expression
of wild type PS2 neither increases Aβ40/42 nor rescues
Notch-associated skeletal defects in embryos. However,
complementation of FAD-associated variants of PS2 selec-
tively elevated Aβ42 levels and rescued Notch-associated
defects. These studies provide compelling support for the
existence of functionally distinct γ-secretase complexes,
and further support the idea of gain of function by FAD-
linked PS variants.
Precisely how FAD-linked PS mutations influence Aβ42
production is still not understood. Altered conformation
has been suggested as a mechanism by which FAD-associ-
ated PS variants may influence specificity of cleavage site
within APP, thus elevating Aβ42 production. For example,
it has been shown that FAD-associated mutations change
the proximity of N- and C-termini of PS1 [83]. On the
other hand, non-steroidal anti-inflammatory drugs such
as sulindac sulfide, ibuprofen, indomethacin and flurbi-
profen, which specifically lower Aβ42 levels without
affecting Aβ40 production [84], decrease the proximity of
PS1 N- and C-terminus and PS1 to APP C-terminus [85].
Nevertheless, how these proximity measures of FAD
mutants relate to conformational changes in the catalytic
site or the substrate-docking site of γ-secretase in a manner
that fosters elevated Aβ42 production remains to be
understood. Recent studies also suggest that the adverse
property of FAD-linked PS alleles is not limited to altering
cleavage site specificity of substrates APP and Notch. For
example, large-scale gene expression profiling in brains of
conditional PS1 knockout mice and transgenic mice
expressing wild type or FAD-linked mutant PS1 suggests
that the FAD-linked PS1 variant produces transcriptome
changes primarily by gain of aberrant function [86]. Fur-
thermore, the expression and activity of neprilysin, an Aβ
degrading enzyme, is regulated by γ-secretase activity. In
vitro studies show that transcription from neprilysin gene
promoter can be activated by cytosolic domains released
from APP, APLP1 or APLP2 by γ-secretase cleavage, and
FAD-associated PS1 mutations increase neprilysin levels
in brains of patients with mutant PS1 alleles [87]. Finally,
since Aβ42 activates neutral sphingomyelinase and Aβ40
inhibits hydroxymethyl-CoA reductase, an indirect role
for PS in maintaining cholesterol and sphingomyelin lev-
els through Aβ40 and Aβ42 production has been pro-
posed [88]. As expected from increased production of
Aβ42, FAD-associated PS1 mutants specifically increase
cellular cholesterol and decrease sphingomyelin levels.
In addition to causing a shift in APP cleavage site, FAD-
associated PS1 mutations may show partial loss of func-
tion in some other physiological activities. PS1 has been
suggested as being involved in not only Aβ generation but
also other processes leading to neurodegeneration.
Tanemura et al. showed that tau was hyperphosphor-
ylated in FAD-associated PS1 mutant (I213T) knock-in
mice in the absence of Aβ deposition [89], whereas neuro-
degeneration of PS conditional double knockout mice is
associated with tau hyperphosphorylation [90]. Part of
the underlying mechanisms might be that PS modulates
PI3K/Akt and ERK signaling pathways to downregulate
GSK-3 activity and tau phosphorylation; and FAD muta-
tions inhibit these pathways in a way similar to that by
PS1 deficiency [91,92]. Moreover, a recent study by Wang
et al. found that melanin synthesis in FAD-associated PS1
M146V knock-in mice was impaired, which was consist-
ent with their observation that γ-secretase inhibitor
blocked melanin synthesis [7].
PS1 regulates trafficking of select membrane proteins
In addition to its function as the catalytic subunit of γ-
secretase, PS directly or indirectly regulates the trafficking
of select membrane proteins. As mentioned above, PS1
deficiency resulted in abnormal intracellular trafficking of
the other three γ-secretase components, nicastrin, APH-1
and PEN-2. In addition, PS1 deficiency in neurons accel-
erated the secretion of α- and β-secretase cleaved APP
ectodomain [93]. Further analysis revealed that PS1 regu-
lates biosynthetic secretory trafficking of APP. Absence of
PS1 or the expression of a loss of function PS1 variant
resulted in increased budding/generation of APP-contain-
ing vesicles from both ER and TGN with a concomitant
increase in complex glycosylation and cell surface appear-
ance of APP [29,94]. In addition, the half-life and steady-
state residence of full length APP and APP CTFs at the cell
surface were greatly increased [95,96]. Interestingly, FAD-
linked PS1 variants significantly reduced budding of APP-
containing vesicles from both ER and TGN, resulting in
decreased delivery of APP to the cell surface [94]. These
findings raised the possibility that FAD-linked PS1 vari-
ants may influence APP processing by increasing the time
of APP residing at the TGN, consequently prolonging their
availability for cleavage by β- and γ-secretases within the
TGN. Direct evidence to support a trafficking role of PS1,
independent of its function in γ-secretase activity,
emerged from analysis of membrane proteins that are not
substrates for γ-secretase cleavage. For example, complex
oligosaccharide modification and brain-derived neuro-
trophic factor-induced phosphorylation of the neuro-
trophin receptor TrkB was severely affected in neurons
lacking PS1 expression [93]. Furthermore, neuron specific
intercellular adhesion molecule (ICAM-5)/telencephalin
accumulated intracellularly in autophagic vacuoles and
displayed extended half-life in the absence of PS1 [97].
Similarly, α- and β-synuclein were found mislocalized in
autophagic organelles in PS1-deficient neurons but not in
neurons treated with selective γ-secretase inhibitors [98].
Remarkably, increased assembly and cell surface delivery
of nicotinic acetylcholine receptors (a mutimeric poly-Molecular Neurodegeneration 2006, 1:4 http://www.molecularneurodegeneration.com/content/1/1/4
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topic membrane protein complex) was observed in cells
expressing a loss of function PS1 mutant that exhibited
accelerated cell surface delivery of APP and slower kinetics
of Aβ secretion [29]. While a role for PS1 in regulating
protein trafficking remains attractive, the growing number
of γ-secretase substrates raises the possibility of impaired
turnover of CTFs derived from type I membrane proteins
indirectly influencing protein trafficking in cells lacking
PS1 expression or γ-secretase activity. Indeed, a recent
study demonstrated that PS deficiency resulted in mislo-
calization of post-Golgi tyrosinase-containing vesicles;
and such an abnormal trafficking of tyrosinase is γ-secre-
tase-dependent and accompanied by simultaneous accu-
mulation of its C-terminal fragment [7]. On the other
hand, there is a possibility that PS1 indirectly regulates
protein trafficking via its interaction with protein traffick-
ing factors. For example, PS1 has been shown to interact
with small factors such as Rab11, Rab6 and Rab GDI that
are involved in regulation of vesicular transport [99-101];
and modulation of Rab6-mediated transport has been
shown to affect APP processing [102]. Recently Cai et al.
also showed that PS1 interacted with phospholipase D1
(PLD1), a phospholipid-modifying enzyme that regulates
membrane trafficking events [103,104]. The results dem-
onstrated that this interaction recruited PLD1 to the
Golgi/trans-Golgi network and thus possibly modulated
APP trafficking, since overexpression of PLD1 promoted
generation of APP-containing vesicles from the TGN.
PS-interacting proteins
Over the past several years many investigators employed
yeast two-hybrid assays and candidate approaches to
identify proteins that interact with various domains of PS
[105] (Fig. 2). As an outcome, several PS interacting pro-
teins have been identified, including members of a family
of armadillo-related proteins such as β-catenin; cell sur-
face transmembrane protein E-cadherin; neuronal cell
adhesion molecule telencephalin; filamin, an actin bind-
ing protein; PBP/MOCA, a protein with limited homology
to Dock180; the enzyme glycogen synthase kinase-3β
microtubule-associated protein tau; calcium binding pro-
teins such as calsenilin, calmyrin, sorcin, mu-calpain and
CALP/KChIP4; anti-apoptotic molecule Bcl-XL; Rab11
and Rab6, small GTPases involved in regulation of vesicu-
lar transport; RabGDI, a regulatory factor in vesicular
transport; PLD1, a phospholipid-modifying enzyme
involved in membrane trafficking events; syntaxin 1A, a t-
SNARE localized in the synaptic plasma membrane; syn-
taxin 5, a t-SNARE that mediates transport between the ER
and Golgi; adaptor proteins X11α and X11β CLIP-170,
the microtubule plus-end-tracking protein; brain G-pro-
tein, Go; Ubiquilin, a protein containing ubiquitin-related
domains; HC5 and ZETA subunits of the catalytic 20S pro-
teasome; TPIP, a tetratricopeptide repeat containing pro-
tein; PAG, a protein of the thioredoxin peroxidase family,
PSAP, a PDZ-like protein, QM/Jif-1, a negative regulator
of c-Jun; DRAL, an LIM-domain protein; proliferation-
associated gene product, a protein of the thioredoxin per-
oxidase family; β-secretase, BACE1; PAMP and PARL, two
novel putative metalloproteases; Omi/HtrA2, a serine
protease involved in the mammalian cellular stress
response; Met1, a novel putative methyltransferase; mito-
chondrial immunophilin FKBP38; a splice variant of glial
fibrillary acidic protein, etc. The C. elegans PS homologue
SEL-12 was recently reported to interact with SEL-10, a
Cdc4p-related protein. In many instances the physiologi-
cal role for the identified interaction between the putative
protein with PS1 or PS2 is not clearly defined. For exam-
ple, the PS interaction with the anti-apoptotic Bcl2 family
member Bcl-XL offers a potential mechanism by which PSs
might regulate apoptosis [106]. However, it is unclear at
present whether an increased apoptotic response associ-
ated with the expression of FAD-linked PS variants noted
in several studies can be attributed to differential interac-
tion of mutant PS1 or PS2 with Bcl-XL. Similarly, the
absence of PS1 or the expression of FAD-linked PS1
mutant results in increased glycogen synthase kinase-3β
activity, enhanced kinesin light chain phosphorylation,
and concomitant reduction in kinesin-based axonal trans-
port [107]. But it remains unclear whether PS1• glycogen
synthase kinase-3β interaction plays a direct role in regu-
lating kinesin-based axonal transport. Finally, it is some-
what puzzling that neither regulated metabolism of PS
nor the enhanced production of Aβ42 by FAD mutants
appears to be influenced by any of the reported PS inter-
acting proteins.
Conclusion
Mutations in PSEN1 and PSEN2 genes co-segregate with
early onset FAD cases and genetic ablation of these genes
eliminates Aβ production in transgenic mice. Replace-
ment of conserved aspartate residues in TM 6 and 7 of PS
resulted in inactivation of γ-secretase activity and PS1 frag-
ments were specifically photolabeled by transition state
analogues of γ-secretase. Taken together these studies
strongly support PS as catalytic subunit of γ-secretase and
γ-secretase as transmembrane aspartyl protease. Abolish-
ment of Aβ production by inhibiting γ-secretase is there-
fore considered a potential therapeutic strategy for the
treatment of AD and several pharmacological inhibitors,
which specifically target processed PS fragments, have
been developed. However, further studies have unraveled
several other functionally important substrates of PS-
mediated γ-secretase cleavage including the type I mem-
brane protein Notch that is critical for development.
These studies indicate that generalized inhibition of γ-
secretase could potentially result in severe consequences
by interfering in other physiological and developmental
processes. It will be more reasonable to develop inhibitors
that specifically target proteolytic processing of APP butMolecular Neurodegeneration 2006, 1:4 http://www.molecularneurodegeneration.com/content/1/1/4
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not other substrates by PS/γ-secretase, which requires log-
ical design and high throughput screening. Recent studies
suggest the use of separate active sites by γ-secretase in the
proteolytic processing of APP and Notch. Further, APP
and Notch processing have been shown to occur in spa-
tially distinct sites. Also interesting is the existence of tis-
sue specific and compositionally distinct γ-secretase
complexes. Therefore, development of specific inhibitors
targeting the active site of γ-sceretase involved in APP
processing or targeting the γ-secretase localized in subcel-
lular membrane microdomain involved in APP process-
ing is promising as a novel therapeutic strategy. The use of
non-steroidal drugs, NSAIDs, has been shown to be effec-
tive in specifically reducing the levels of Aβ42 peptides
without affecting Aβ40 production and Notch processing.
The mechanism of FAD-associated PS variants in elevating
levels of Aβ42 is still being explored. Altered conforma-
tion and proximity of PS1-derived fragments themselves
or with the substrate APP were shown to be the possible
cause for the pathogenic functions of FAD-associated PS1
variants. It is still intriguing how widely scattered FAD-
associated PS1 mutants have the same functional effect on
APP processing. PS1 has been shown to be involved in the
subcellular trafficking of APP and FAD-linked PS1 vari-
ants increase the retention of substrate in compartments
where γ-secretase was localized. Experimental mutations
are quite useful in identifying the functions of the individ-
ual domains of PS1. Transgenic mice with conditional
ablation of PS1 and expression of FAD-associated human
PS variants have provided some clues about the physio-
logical consequences and stages in the development of
disease. In contrast to PS1, not much information is avail-
able on the functions of PS2 or PS2-mediated γ-secretase
complex. Most of the aggressive forms of FAD cases (less
than 30 years of age at onset) are associated with PS1
rather than PS2. The lesser frequency of FAD-linked PS2
mutations compared to that of PS1 also suggests a redun-
dant role for PS2 containing γ-secretase complexes. But
interestingly, FAD-associated variant PS2N141I is able to
rescue Notch-associated developmental defects compared
to PS2 wt in the absence of PS1, which makes the precise
functions of different PS/γ-secretase complexes perplex-
ing. On the other hand, several PS interacting proteins
have been identified but the functional relevance of such
interactions is still not completely elucidated. Since the
first clue for PS association in FAD was identified a decade
ago, we have gained more insights into these novel pro-
teins. Nonetheless with the information we gained on
these proteins, finding a cure for the devastating AD is still
promising.
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